“…Given the clinical validation of targeting FFA1, there remains significant interest in the potential of novel ligands at this receptor for the treatment of T2DM 14 , 15 , 16 . Recent publications from various pharmaceutical companies several, of what appear, at least in animal models, to be highly effective and potent FFA1 ligands 17 , 18 , 19 , support this. Clearly, issues akin to those that resulted in the removal of fasiglifam from clinical development, including inhibition of BSEP, would need to be addressed directly before further clinical studies commence.…”